Skip to main content
Elanix Biotechnologies AG logo

Elanix Biotechnologies AG — Investor Relations & Filings

Ticker · ELN ISIN · DE000A0WMJQ4 LEI · 391200SYNFFL0NPAJK90 F Manufacturing
Open in API
Filings indexed 161 across all filing types
Latest filing 2018-11-29 Declaration of Voting R…
Country DE Germany
Listing F ELN

About Elanix Biotechnologies AG

https://elanixbiotechnologies.com/

Elanix Biotechnologies AG is a tissue regeneration company that develops and commercializes products for acute wound care, dermatological, and gynecological applications. The company's core focus is on creating therapeutic solutions derived from progenitor cells. Its product development pipeline aims to provide advanced treatments for skin and tissue repair.

Recent filings

Filing Released Lang Actions
Declaration of Voting Results & Voting Rights Announcements 2018
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is explicitly titled 'Voting Rights Announcements' and contains detailed tables regarding the 'Notification of Major Holdings' under German securities law (WpHG). It specifies the acquisition/disposal of shares with voting rights, the percentage of voting rights held (17.76%), and the date the threshold was crossed. This directly corresponds to the definition of a major shareholding notification, which in the provided list maps to 'Major Shareholding Notification' (MRQ). Although the header mentions 'Voting Rights Announcements', the content is a formal disclosure of a significant change in share ownership.
2018-11-29 English
Elanix Biotechnologies AG: Professor Laurent-Applegate, founder and Interim-CEO, announces sale of shares in Elanix Biotechnologies AG
Director's Dealing Classification · 99% confidence The document is an 'Ad-hoc' announcement dated November 23, 2018, disclosing that the founder and Interim-CEO, Professor Laurent-Applegate, intends to sell 1,434,872 shares (17.8% of the company) to a strategic investor. This type of filing, reporting personal share transactions by a director/executive, directly corresponds to the definition of 'Director's Dealing'. The filing explicitly mentions disclosure under MAR (Market Abuse Regulation), which often covers insider transactions. Therefore, the appropriate code is DIRS.
2018-11-23 English
Elanix Biotechnologies AG: Frau Prof. Lee Ann Laurent-Applegate wird neuer Vorstand
Board/Management Information Classification · 100% confidence The document is a news release dated November 12, 2018, announcing that 'Frau Prof. Lee Ann Laurent-Applegate wird neuer Elanix Biotechnologies AG Vorstand' (Ms. Prof. Lee Ann Laurent-Applegate becomes a new board member of Elanix Biotechnologies AG). This explicitly details a change in senior management/board composition. This directly matches the definition for Board/Management Information (MANG). The document is short and formatted like a regulatory news wire announcement (DGAP-News), but the core content is the management change, not the announcement of a report itself.
2018-11-12 German
Elanix Biotechnologies AG: Widerruf der Bestellung von Herrn Tomas J. Svoboda (CEO) als Vorstandsmitglied
Board/Management Information Classification · 100% confidence The document is an 'Ad-hoc' announcement dated November 12, 2018, titled 'Widerruf der Bestellung von Herrn Tomas J. Svoboda (CEO) als Vorstandsmitglied' (Revocation of the appointment of Mr. Tomas J. Svoboda (CEO) as a member of the Management Board). It explicitly states it is an 'Insiderinformationen nach Artikel 17 der Verordnung (EU) Nr. 596/2014' (Inside Information according to Article 17 of Regulation (EU) No 596/2014). This type of announcement concerns a significant change in senior management (CEO and CFO) and is a mandatory disclosure. This directly matches the definition for Board/Management Information (MANG). The document length is short (4213 chars) and it is a direct announcement, not a report itself.
2018-11-12 German
Elanix Biotechnologies AG: Elanix Biotechnologies AG has placed 301,763 shares of the current cash capital increase and is negotiating further financing opportunities
Share Issue/Capital Change Classification · 99% confidence The document explicitly discusses the completion of a 'cash capital increase' resulting in gross proceeds and an increase in share capital. It also mentions negotiating 'further financing opportunities'. This content directly relates to fundraising, financing activities, and changes in capital structure. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document is a formal news release (indicated by DGAP-News) detailing a specific financial transaction, not just an announcement of a report.
2018-10-01 English
Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Total Voting Rights Announcement' and explicitly mentions the 'Publication of total number of voting rights'. It details a capital measure ('Other capital measure' under Sec. 41 para. 1 WpHG) and states the 'New total number of voting rights' is 8,080,902. This type of announcement, concerning the total number of shares/voting rights, is a specific regulatory disclosure. It is not a full financial report (10-K, IR), an earnings release (ER), or a management presentation (IP). It most closely aligns with a regulatory disclosure regarding capital structure or shareholder rights, which falls under the scope of general regulatory announcements or specific capital structure updates. Since it is a direct announcement about the total voting rights count, it is a specific regulatory filing. Given the options, 'Declaration of Voting Results & Voting Rights Announcements' (DVA) is the most precise fit for an announcement detailing the total voting rights count, even if it's not the result of a specific vote, as it relates directly to the voting structure. However, since it is a general regulatory disclosure about the capital structure/voting rights count, and not a result of a vote, 'Regulatory Filings' (RNS) serves as a strong general category, but DVA specifically addresses voting rights. Given the context of WpHG (German Securities Trading Act) and the focus on 'Total Voting Rights', DVA is the most targeted classification.
2018-09-28 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.